PharmaShots | Incisive News in 3 Shots

Subscribe Now

BLA for IBI-305

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC

January 29, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us